Opthea (OPT.AX) Stock Price
Opthea Price
Revenue at Opthea has contracted by 18.3% per year over the past 19 years to 25,000 USD. For Opthea, the net margin of -651,164% is down versus -66,099.9% a few years ago.
Opthea stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Opthea over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Opthea stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Opthea's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Opthea Price |
|---|
Opthea Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Opthea Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| DIVIDEND (USD)DIV. (USD) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (B) |
| DOCUMENTS |
| 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 3 | 10 | 13 | 17 |
| – | – | – | – | – | 233.33 | 30 | 30.77 |
| – | – | – | – | 100 | 100 | 100 | 100 |
| 1 | 1 | 1 | 1 | 3 | 10 | 13 | 17 |
| -220 | -162 | -3 | -3 | -23 | 38 | 114 | 173 |
| 54.93 | -26.36 | -98.15 | – | 666.67 | -265.22 | 200 | 51.75 |
| - | - | - | - | - | - | - | - |
| – | – | – | – | – | – | – | – |
| 0.64 | 1.22 | 1.22 | 1.22 | 1.22 | 1.22 | 1.22 | 1.22 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Opthea generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Opthea retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Opthea's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Opthea has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Opthea's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Opthea stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Opthea Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Opthea business model & stock analysis
Opthea SWOT Analysis
Strengths
Opthea Ltd possesses several strengths that contribute to its success in the market. The company has a strong and dedicated research and development team, constantly working towards developing innovative solutions in the field of ophthalmology. This provides Opthea with a competitive advantage over its competitors. Additionally, Opthea has established strategic collaborations with renowned pharmaceutical companies, which enhances its research capabilities and market presence.
Weaknesses
Despite its strengths, Opthea Ltd also faces certain weaknesses. One of the major weaknesses is its heavy reliance on a limited product portfolio. The company currently heavily depends on a single drug candidate for its revenue generation. This makes Opthea vulnerable to any setbacks or failures associated with that particular product. Moreover, Opthea's financial resources are relatively limited, hindering its ability to invest in additional research and development projects.
Opportunities
Opthea Ltd has identified several opportunities that can be leveraged to its advantage. The growing global prevalence of eye disorders presents a significant market opportunity for Opthea to introduce new treatment options. Furthermore, the company can explore potential partnerships with academic institutions or research organizations to expand its research capabilities and tap into new markets. Additionally, the increasing focus on personalized medicine provides Opthea with an opportunity to develop tailored treatments for specific subgroups within the ophthalmology field.
Threats
Opthea Ltd also faces several threats that could potentially impact its operations. One of the significant threats is the intense competition within the ophthalmology sector. The presence of well-established competitors with robust product portfolios poses a challenge for Opthea to differentiate itself in the market. Additionally, regulatory uncertainties and stringent approval processes in the pharmaceutical industry may result in delays or restrictions for Opthea's drug candidates. Moreover, any negative results or safety concerns in clinical trials could pose a threat to the company's reputation and financial stability.
Opthea Segments
Opthea Eulerpool Fair Value
Opthea historical P/E ratio, EBIT multiple, and P/S ratio
Opthea annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Opthea shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Opthea Dividend History
2 years of dividend payments
Opthea Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 2/21/2024 | -0.12USD | 45,450USD | 2024 Q2 |
| 8/27/2023 | -0.1USD | 228,374USD | 2023 Q4 |
| 2/27/2023 | -0.12USD | 224,995USD | 2023 Q2 |
| 8/30/2022 | -0.03USD | -USD | 2022 Q4 |
| 2/28/2022 | -0.09USD | 0USD | 2022 Q2 |
| 8/30/2021 | 0.03USD | 454,719USD | 2021 Q4 |
| 2/22/2021 | 0.05USD | 583.63 MUSD | 2021 Q2 |
| 8/28/2020 | -0.09USD | 0USD | 2020 Q4 |
| 2/26/2020 | -0.09USD | 0USD | 2020 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Opthea stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Opthea shareholder structure
| % | Name |
|---|---|
30.08682% | |
5.0731% | |
1.63343% | |
1.61724% | |
1.14352% | |
1.12317% |
Opthea Executives and Management Board
Dr. Megan Baldwin
(49)Founder, Chief Innovation Office · since 2009
Mr. Lawrence Gozlan
(44)Non-Executive Independent Director
Mrs. Karen Adams
(52)Vice President - Finance, Company Secretary
Dr. Jeremy Levin
(71)Non-Executive Independent Chairman of the Board
Dr. Julia Haller
(69)Non-Executive Independent Director
Opthea Supply Chain
Frequently asked questions about Opthea
Opthea Ltd operates under a unique business model. This biopharmaceutical company primarily focuses on the development of novel therapies for the treatment of eye diseases. Opthea aims to address unmet medical needs, particularly in the field of ophthalmology, by leveraging its expertise in the fields of VEGF (Vascular Endothelial Growth Factor) biology and protein engineering. By developing innovative and effective treatments, Opthea strives to improve the lives of patients suffering from vision-related disorders. With their commitment to advancing cutting-edge research and therapies, Opthea Ltd has positioned itself as a key player in the ophthalmic pharmaceutical industry.
Opthea stock
Opthea Peer Group
Opthea Ticker
Opthea FIGI
All fundamentals and in-depth analysis of Opthea
Our stock analysis for Opthea stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Opthea. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.